Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?

Auteurs-es

  • Sherry Rohekar

Résumé

As 2024 continues to evolve, so do treatment recommendations for the management of spondyloarthritis (SpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). From a Canadian perspective, we eagerly await the publication of the Canadian Rheumatology Association (CRA)/Spondyloarthritis Research Consortium of Canada (SPARCC) Living Treatment Recommendations for the Management of Axial Spondyloarthritis (axSpA), currently in press. Until these recommendations for axSpA treatment with a Canadian perspective arrive  – where are we now?

Biographie de l'auteur-e

Sherry Rohekar

Dr. Sherry Rohekar completed medical school at the University of Western Ontario, and then went on to train in general internal medicine at Queen’s University and rheumatology at the University of Toronto. She also has a Master’s of Clinical Epidemiology from UWO. She is now an Associate Professor in the Department of Medicine, Division of Rheumatology at UWO. Her research and clinical interest is spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis. She is currently on the executive committee the SPondyloArthritis Research Consortium of Canada, and member of the International Psoriasis and Arthritis Research Team, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and the SPondyloArthritis Research & Treatment Network.

Références

Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71(10):1285–1299. doi: 10.1002/acr.24025

Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34. doi: 10.1136/ard-2022-223296

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926. doi: 10.1136/bmj.39489.470347.AD

Centre for Evidence-Based Medicine. Oxford Centre for Evidence-Based Medicine:The Oxford 2009 levels of evidence. [Updated: 2024, Cited: 14 Jun 2024]. Available at: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-forevidence- based-medicine-levels-of-evidence-march-2009.

Sinnappan S, Forte A, Ermann J. Axial spondyloarthritis treatment recommendations and disease activity monitoring in clinical practice: results of an online survey. J Rheumatol. 2024;51(5):472–478. doi: 10.3899/jrheum.2023-0894.

Akl EA, Meerpohl JJ, Elliott J, Kahale LA, Schünemann HJ, Living Systematic Review Network. Living systematic reviews: 4. Living guideline recommendations. J Clin Epidemiol. 2017;91:47–53. doi: 10.1016/j.jclinepi.2017.08.009

Elliott JH, Synnot A, Turner T, Simmonds M, Akl EA, McDonald S, et al. Living systematic review: 1. Introduction-the why, what, when, and how. J Clin Epidemiol. 2017;91:23–30. doi: 10.1016/j.jclinepi.2017.08.010

Hazlewood GS, Pardo JP, Barnabe C, Schieir O, Barber CEH, Proulx L, et al. Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying anti-rheumatic drugs [version 2.1]. [Internet]. [cited 25 Nov 2023]. Available from: https://app.magicapp.org/#/guideline/7413

Téléchargements

Publié

2024-09-17

Comment citer

1.
Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?. Can Rheumatol Today [Internet]. 17 sept. 2024 [cité 19 avr. 2026];1(2):41–46. Disponible à: https://canadianrheumatologytoday.com/article/view/1-2-Rohekar

Numéro

Volume 1, Issue 2, Summer 2024

Rubrique

Articles

Licence

© Canadian Rheumatology Today 2024

Licence Creative Commons

Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.

Comment citer

1.
Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?. Can Rheumatol Today [Internet]. 17 sept. 2024 [cité 19 avr. 2026];1(2):41–46. Disponible à: https://canadianrheumatologytoday.com/article/view/1-2-Rohekar